“When you start talking about frontline therapies and going into very large solid tumor indications, there’s going to be a much larger bar,” she said. The risk of a lentiviral vector binding to a malignant B cell rather than a T - cell , giving cancerous CAR - expressing cells the ability to hide from CAR - T cells that cause leukaemia , may hamper the manufacturers of CAR - T cells such as Novartis and Gilead , which make it and Yescarta respectively , according to a study by the University of Oxford . A 20-year old patient died as a result of the incident . Though rare , such an incident would be a bigger deal for a patient starting therapy than for a patient with months left to live , said Anthony Davies of Dark Horse Consulting .
The risk of a lentiviral vector binding to a malignant B cell rather than a T - cell , giving cancerous CAR - expressing cells the ability to hide from CAR - T cells that cause leukaemia , may hamper the manufacturers of CAR - T cells such as Novartis and Gilead , which make it and Yescarta respectively , according to a study by the University of Oxford . A 20-year old patient died as a result of the incident . Though rare , such an incident would be a bigger deal for a patient starting therapy than for a patient with months left to live , said Anthony Davies of Dark Horse Consulting .